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The International Germ Cell Consensus (IGCC) classification identifies good, intermediate and poor prognosis groups among patients
with metastatic nonseminomatous germ cell tumours (NSGCT). It uses the risk factors primary site, presence of nonpulmonary
visceral metastases and tumour markers alpha-fetoprotein (AFP), human chorionic gonadotrophin (HCG) and lactic dehydrogenase
(LDH). The IGCC classification is easy to use and remember, but lacks flexibility. We aimed to examine the extent of any loss in
discrimination within the IGCC classification in comparison with alternative modelling by formal weighing of the risk factors. We
analysed survival of 3048 NSGCT patients with Cox regression and recursive partitioning for alternative classifications. Good,
intermediate and poor prognosis groups were based on predicted 5-year survival. Classifications were further refined by subgrouping
within the poor prognosis group. Performance was measured primarily by a bootstrap corrected c-statistic to indicate discriminative
ability for future patients. The weights of the risk factors in the alternative classifications differed slightly from the implicit weights in the
IGCC classification. Discriminative ability, however, did not increase clearly (IGCC classification, c¼0.732; Cox classification,
c¼0.730; Recursive partitioning classification, c¼0.709). Three subgroups could be identified within the poor prognosis groups,
resulting in classifications with five prognostic groups and slightly better discriminative ability (c¼0.740). In conclusion, the IGCC
classification in three prognostic groups is largely supported by Cox regression and recursive partitioning. Cox regression was the
most promising tool to define a more refined classification.
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Testicular germ cell tumours (seminomatous and nonseminoma-
tous) are the most common cancers among young adult men. Since
the 1970s, long-term cure rates of patients with germ cell tumours
have increased to over 80%, because of the ability of cisplatin-
based chemotherapy to cure advanced disease (Bosl and Motzer,
1997; Hartmann et al, 1999; Steele et al, 1999; Sonneveld et al,
2001). Owing to the high overall cure rate, interest has shifted from
increasing the overall cure rate to reducing treatment-related
toxicity for patients with a good prognosis (de Wit et al, 2001). On
the other hand, high-risk patients, eligible for more intensive
treatment, for example, stem-cell support or high-dose chemother-
apy, should be identified (Bokemeyer et al, 1999, 2002).
Several classifications have been proposed in the past to
distinguish patients according to prognosis, by identifying and
combining the main prognostic factors for progression-free
survival (PFS) and overall survival (Bajorin et al, 1988, 1991;
Mead et al, 1992). The coexistence of classifications differing in
type, complexity and ability to separate good from poor prognosis
complicated international collaboration in randomised trials and
made comparison of nonrandomised studies impossible. Interna-
tional collaboration by the International Germ Cell Cancer
Collaborative Group resulted in the development of the Interna-
tional Germ Cell Consensus Classification (IGCC classification),
which is widely applied and easy to use and remember (IGCCCG,
1997).
For the IGCC classification, readily available risk factors were
selected from a wider set following Cox regression analyses,
namely primary site, presence of nonpulmonary visceral metas-
tases (NPVM) and elevation of the tumour markers alpha-
fetoprotein (AFP), human chorionic gonadotrophin (HCG) and
lactic dehydrogenase (LDH). All variables were categorical, since
no major differences in performance were found compared to
using continuous variables (McCaffrey et al, 1998). In Table 1, how
the risk factors were combined into three prognostic groups for
patients with nonseminomatous germ cell tumours (NSGCT) with
either good, intermediate or poor prognosis are shown. The good
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lprognosis group is characterised by the absence of adverse risk
factors. The intermediate prognosis group is defined by the
presence of any intermediate tumour marker, that is, one or more
intermediate tumour markers are present. The poor prognosis
group is characterised by the presence of any of the poor risk
factors mediastinal primary site, NPVM, AFP poor, HCG poor or
LDH poor, that is, one or more poor risk factors are present. The
classification can be seen as a max function where the good,
intermediate and poor prognosis groups have a maximum score of
zero, one or two, respectively.
In the IGCC classification, all intermediate tumour markers and
all poor risk factors were required only to be sufficiently bad to be
classified as intermediate and poor prognosis, respectively, that is,
differences in importance between intermediate tumour markers
and differences in importance between poor risk factors are not
taken into account. Furthermore, no distinction is made between
the number of intermediate tumour markers in the intermediate
prognosis group and the number of poor risk factors in the poor
prognosis group. Better discrimination might be achieved by
incorporating differences in predictive strength and testing
specific interaction terms.
Furthermore, it is difficult to adjust the current classification for
changes in treatment strategy. A more flexible scoring system
could more easily identify subgroups for the identification of very
high risk patients eligible for novel chemotherapy approaches such
as high-dose chemotherapy or the use of novel cytotoxic agents
(Bokemeyer et al, 1999; Kollmannsberger et al, 2000). We however
note that an important consideration in developing the IGCC
classification was that all the prognostic groups should be large
enough to make randomised trials of new treatments for each
prognostic group feasible (IGCCCG, 1997).
The aim of this study was to reconsider steps taken in the
development of the IGCC classification, and to investigate
alternative classifications based on Cox regression and recursive
partitioning (Breiman et al, 1984) that may discriminate better and
be more suitable to identify more subgroups.
MATERIALS AND METHODS
Patients
Centres participating in the International Germ Cell Collaborative
Group provided retrospective data of 5202 adult male patients with
NSGCT. All patients were treated between 1975 and 1990 with
cisplatin-based chemotherapy. Data were collected on age, primary
site, date of diagnosis, levels of serum AFP, HCG and LDH, nodal
disease in the abdomen, mediastinum, and neck, lung metastases,
spread to other visceral sites like liver, bone and brain and on
treatment details like previous therapy. For the development of the
IGCC classification, patients without missing data on the risk
factors primary site, NPVM, tumour markers AFP, HCG and LDH
and the outcome survival were selected (n¼3048) (IGCCCG,
1997).
Outcome and IGCC risk factors
The outcome measures were PFS and overall survival from the
start of the chemotherapy. The risk factors in the IGCC
classification were primary site (testis/retroperitoneal vs medias-
tinum), presence of NPVM (yes/no) and tumour markers AFP,
HCG and LDH. Each tumour marker had three categories; good,
intermediate and poor with specific cutoff points on the
continuous tumour markers (see Table 1) (IGCCCG, 1997). The
same risk factors and categories were used to construct the
alternative classifications based on Cox regression and recursive
partitioning.
Statistical analyses
The IGCC classification makes no clear distinction between the
intermediate tumour markers and between the poor risk factors
and is represented by a max score. One way to assess this
assumption is by evaluating whether the weights in the IGCC
classification were optimally allocated to the risk factors. We
hereto varied the IGCC weights (1/2) over the levels of the risk
factors and compared all possible combinations with respect to
performance. Performance was quantified by the difference in
minus twice the log likelihood (model w
2) (Clayton and Hills,
1993).
We used the Cox regression to study the univariable and
multivariable effects of the IGCC risk factors on the overall
survival, expressed as Hazard ratios and regression coefficients.
The Cox regression model formed the basis of classification ‘5R’.
We multiplied the multivariate regression coefficients by 10 and
rounded them to obtain weights. A sum score was calculated by
multiplying the weights with individual patient characteristics and
adding the resulting individual scores (Assmann et al, 2002). We
calculated the estimated 5-year survival rate for each score.
The IGCC classification can be viewed as implying that the risk
factors are strongly dependent, that is, that there are interactions
between risk factors. There is, for example, no distinction made
between patients with one poor risk factor or three poor risk
factors. To test whether and which interactions were present, we
added all two-way interactions between the IGCC risk factors in a
Cox regression model. Important interactions were selected
through stepwise backward selection (Po0.05). Since interactions
based on small number of patients give unreliable regression
coefficients, the interaction terms were defined as linear. The
resulting model forms the basis of classification ‘5Ri’. A sum score
based on a regression model with interactions is, however, more
difficult to calculate and interpret. Therefore, a table was
constructed with 5-year survival estimates for all possible
combinations of the IGCC risk factors based on the Cox regression
model with linear interactions. The number of patients on which
Table 1 International Germ Cell Consensus Classification for nonsemi-
noma
Good prognosis
Testis/retroperitoneal primary site¼0
and
No nonpulmonary visceral metastases¼0
and
AFP good¼0 and HCG good¼0 and LDH good¼0
Max¼0
Intermediate prognosis
Testis/retroperitoneal primary site¼0
and
No nonpulmonary visceral metastases¼0
and
AFP intermediate¼1 or HCG intermediate¼1 or LDH intermediate¼1
Max¼1
Poor prognosis
Mediastinal primary site¼2
or
Nonpulmonary visceral metastases¼2
or
AFP poor¼2 or HCG poor¼2 or LDH poor¼2
Max¼2
Tumour markers AFP/HCG/LDH: Good – AFP o1000ngml
 1, HCG o5000iul
 1,
LDH o1.5 upper limit of normal; Intermediate – AFP 1000–10000ngml
 1,H C G
5000–50000ngml
 1, LDH 1.5–10 N; Poor – AFP 410000ngml
 1, HCG
450000iul
 1,L D H410 N.
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leach survival estimate was based is given to indicate the reliability
of the survival estimates.
An alternative and visually more attractive way of exploring and
presenting interactions between risk factors is by growing a tree
through recursive partitioning (Breiman et al, 1984; Segal and
Bloch, 1989; Ahn and Loh, 1994) that we used to construct
classification ‘5T’. A binary tree is built by the following process:
first the risk factor that best splits the data into two groups, leading
to the largest decrease in prediction error, is determined (recursive
partitioning or splitting method). Splitting continues until the
subgroups reach a minimum size or until no improvement can be
made (stopping rule). The full tree, which is often too complex and
overfit, is pruned using crossvalidation. All trees within one
standard error of the lowest crossvalidated prediction error are
considered as equivalent. From these equivalent trees, the simplest
is chosen as final tree (Breiman et al, 1984).
As a splitting method, the exponential scaling method was used
(Therneau et al, 1990; LeBlanc and Crowley, 1992). The splitting
process stopped when a minimum of five patients per groups was
reached or when there was no further decrease in prediction error.
We used 10-fold crossvalidation to determine the optimal tree size.
Modelling was performed with S-plus version 2000 using the
RPART library that contains a recursive partitioning method for
survival data.
The RPART library (rpart2.zip) and manual (rpart2doc.zip) can
be found at http://www.stats.ox.ac.uk/pub/SWin.
Prognostic groups
In all classifications, three prognostic groups were identified using
the estimated 5-year survival by sum score (classification 5R),
combination of risk factors (5Ri) or binary tree (5T). Subgroups
with a 5-year survival higher than 90% were considered as good
prognosis, between 65 and 89% as intermediate prognosis, and
lower than 65% as poor prognosis.
Furthermore for each classification, we explored the possibility
of identifying more subgroups. For the IGCC classification, this
was carried out by allowing weights to vary from zero to four
(instead of zero to two), and comparing all possible combinations
on performance. For classifications 5R, 5Ri and 5T, we changed the
cutoff points on estimated 5-year survival. A 5-year survival rate
higher than 90% was considered as good prognosis, 75–89% as
intermediate prognosis, 60–74% as good-poor prognosis, 40–59%
as intermediate-poor prognosis, and lower than 40% as poor-poor
prognosis (Kollmannsberger et al, 2000). Survival of the five
groups of the IGCC classification and classifications 5R, 5Ri and 5T
was presented by Kaplan–Meier curves.
Performance
The classifications were evaluated by their ability to distinguish
between patients differing in survival. An indication of the
discriminative ability is the difference in 5-year survival rates
between the good, intermediate and poor prognosis groups. A c-
statistic was also calculated for both the three and five group
classifications. For binary outcomes, the c-statistic is similar to the
area under the ROC curve (Harrell et al, 1984). The c-statistic for
survival data indicates the probability that for a randomly chosen
pair of patients, the one having the higher predicted survival is the
one who survives longer (Harrell et al, 1984). Overall performance
of the three and five group classifications was measured by model
w
2. When a model is developed and evaluated on the same data, the
performance of the model is usually too optimistic. The optimism
can be quantified with statistical methods, known as internal
validation techniques (Steyerberg et al, 2001). To estimate and
correct for the optimism in discriminative ability, the steps taken
in the Cox regression and recursive partitioning were internally
validated by taking random bootstrap samples (100) (Efron and
Tibshirani, 1993; Harrell et al, 1996).
RESULTS
The median follow-up time of surviving patients was 50 months.
Disease progression occurred in 680 patients, and 533 patients
died. The 5-year PFS was 78% (95% CI 76–79%) and the 5-year
overall survival 82% (95% CI 81–84%). Most patients had as
primary site testis or retroperitoneum (97%), no NPVM (92%),
and good AFP, HCG and LDH levels (84, 87 and 67%, respectively)
(Table 2). All risk factors were predictors of survival as indicated
by the Hazard ratios ranging from 2.1 to 6.2, where the tumour
marker AFP was the weakest risk factor in the univariable analysis.
Alternative classifications
The regression-based weights of the risk factors in classification
5R, and the cutoff points on the resulting sum score are presented
in Table 3, with the weights and cutoff points of the IGCC
classification.
The weights suggest that differences between risk factors were
present. Tumour marker AFP had a much lower weight in the
multivariate analysis than tumour markers HCG and LDH. As a
result, a poor AFP level (score 3) is not sufficient to be classified as
poor prognosis in classification 5R. Also, the combination of two
or three intermediate tumour markers, which would lead to an
intermediate prognosis in the IGCC classification, results in a score
of over 10 and thus in classification in the poor prognosis group in
classification 5R. The presence of risk factor NPVM (score 7) alone
was not sufficient to be classified as poor prognosis, in contrast
with the IGCC classification. Patients would only be classified as
poor prognosis when other risk factors besides NPVM or AFP are
present.
We identified four significant interactions in the Cox regression
model; between AFP and primary site (Po0.001), AFP and NPVM
(Po0.01), HCG and NPVM (Po0.003) and HCG and LDH
Table 2 Characteristics of 3048 NSGCT patients on the IGCC risk
factors
IGCC risk
factors
Number of
patients (%)
5-year
survival (%)
95%
CI (%) HR
95%
CI
Primary site
Testis/retroperitoneal 2947 (97) 84 82–85 1 —
Mediastinum 101 (3) 37 27–47 6.1 4.7–7.9
NPVM
No 2808 (92) 85 84–86 1 —
Yes 240 (8) 49 42–55 4.6 3.8–5.6
AFP
Good 2559 (84) 85 84–87 1 —
Intermediate 349 (12) 71 66–76 2.1 1.7–2.6
Poor 140 (5) 56 47–65 3.6 2.7–4.7
HCG
Good 2656 (87) 86 84–87 1 —
Intermediate 238 (8) 65 58–71 3.0 2.3–3.8
Poor 154 (5) 48 39–56 5.0 3.9–6.4
LDH
Good 2036 (67) 89 88–91 1 —
Intermediate 977 (32) 68 65–71 3.3 2.8–3.9
Poor 35 (1) 51 34–67 6.2 3.9–10.1
Total number subjects 3048 (100) 82 81–84 — —
NPVM¼nonpulmonary visceral metastases.
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l(Po0.01). The regression coefficients all had negative signs,
indicating that the effect of the risk factors together was smaller
than the sum of their separate effects. For all 108 combinations of
the IGCC risk factors, we present 5-year survival estimates from
the Cox regression model with interactions (Appendix). Patients
with testis as primary site and good or intermediate tumour
markers had the highest estimated survival (55–92%). Patients
with mediastinum as primary site and NPVM had the worst
estimated survival (0–64%). Since the number of patients with
more than one poor risk factor was limited, the survival estimates
for these patients were less reliable. Recursive partitioning resulted
in a tree with seven subgroups with 5-year survival ranging from
35 to 91% (Figure 1), forming the basis of classification 5T.
Tumour marker LDH was the principal determinant of 5-year
survival, making a split between good LDH (N¼2036) and
intermediate/poor LDH (N¼1012). The majority of the ‘good
LDH’ subgroup consists of patients with no risk factors (N¼1865)
with an observed 5-year survival of 91% (95% CI 90–93%).
Furthermore, a subgroup of 29 patients with primary site
mediastinum had a 5-year survival of 55% (95% CI 34–72%)
and patients with intermediate or poor HCG (N¼142) had a 5-
year survival of 70% (95% CI 61–77%). Within the subgroup
intermediate/poor LDH, four further subgroups were identified
with the risk factors NPVM, primary site and HCG, with 5-year
survival ranging from 35 to 80%.
Performance
The 5-year survival rates for the good, intermediate and poor
prognosis groups were comparable for the IGCC classification and
classifications 5R, 5Ri and 5T (Table 4). The c-statistic of the IGCC
classification was 0.732. The apparent c-statistics of classifications
5R, 5Ri and 5T were 0.732, 0.735 and 0.718, respectively. Validation
showed minor optimism in the c-statistic in the Cox regression
models (0.002). More optimism was present in the classification
5T, with the c-statistic decreasing from 0.718 to 0.709. Classifica-
tion 5R did not show an improvement in model w
2 compared to the
IGCC classification (model w
2 402 and 401, respectively, 2d.f.).
Classifications 5Ri did show a statistically significant increase in
overall performance over the IGCC classification (model w
2 422,
2d.f.). Classification 5T had a worse overall performance with a
model w
2 of 374 (2d.f.).
Identification of more subgroups
Within the max score, different weights did not lead to an
improvement in overall performance over the weights of the IGCC
classification (model w
2 402, 2d.f.). The following weights were
allocated to derive a max function with five prognostic groups in
the IGCC classification with the score varying between 0 and 4;
primary site mediastinum (4), NPVM (3), AFP good/intermediate/
poor (0/1/2), HCG good/intermediate/poor (0/2/3) and LDH good/
intermediate/poor (0/1/3). The 5-year survival varied from 37 to
92% for the five groups of the IGCC classification, from 34 to 92%
for classification 5R, from 36 to 92% for classification 5Ri and from
35 to 91% for classification 5T (Table 5). The cutoff points on the
sum score for the five groups of classification 5R are also given in
Table 5. The difference in survival between the prognostic groups
for each classification is illustrated in Figure 2. The c-statistic for
the five groups of the IGCC classification and classifications 5R
and 5Ri was slightly higher than for the three group classifications
(0.739, 0.741 and 0.744, respectively) and with a small amount of
optimism (0.002) for the Cox regression models. The increase of
the c-statistic for the five groups of classification 5T was very
limited (0.722) with an optimism of 0.011. The increase in model w
2
was more substantial; 422 for the extended IGCC classification, 446
for classification 5R, 450 for classification 5Ri. The increase in
model w
2 for classification 5T (383) was less substantial.
DISCUSSION
The discriminative ability of classifications derived through Cox
regression and recursive partitioning was in concordance with the
IGCC classification and therefore supports the validity of the IGCC
classification. We did, however, find that not all intermediate
tumour markers and poor risk factors were equally important, and
that taking these differences into account does affect the
classification of patients. In Cox regression-based classifications,
especially risk factors NPVM and AFP had less impact compared
to the other risk factors. That AFP is of less importance than the
other risk factors is confirmed by recursive partitioning where AFP
Table 3 Weights, coding of variables, and cutoff on the max function of
the IGCC classification and the sum score of the regression-based
classification 5R
Classification IGCC 5R
Risk factors
in the model
Coding of
risk factors
Implicit
weights
Regression
weights
Primary site Testis/retroperitoneal 0 0
Mediastinum 2 15
NPVM No 0 0
Yes 2 7
AFP Good 0 0
Intermediate 1 2
Poor 2 3
HCG Good 0 0
Intermediate 1 9
Poor 2 11
LDH Good 0 0
Intermediate 1 7
Poor 2 9
Cutoff points Good Max 0 Sum 0
Intermediate 1 2–10
Poor X2 X11
NPVM¼nonpulmonary visceral metastases.
| 533/3048
89%
217/2036
90%
178/1894
91%
165/1865
55%
13/29
70%
39/142
67%
316/1012
73%
217/832
76%
188/786
80%
119/619
57%
69/167
35%
29/46
44%
99/180
82%
LDH good LDH int/poor
HCG int/poor HCG good
Primary site
mediastinum
NPVM no NPVM yes
Primary site
 testis
Primary site
mediastinum
HCG good HCG int/poor
Poor
Intermediate Poor
Poor
Intermediate Poor
Primary site
testis
Good
Figure 1 The final tree fitted by recursive partitioning, using the
exponential scaling method. The 5-year survival rates, events and total
number of observations per subgroup are given. The resulting subgroups
are displayed in rectangulars and determine classification 5T.
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lwas not selected in the final tree. Furthermore, not all risk factors
had statistical interactions. In classifications 5Ri and 5T, only a
limited number of interactions were included. Combining several
risk factors led to differences in 5-year survival, that is, patients
with one poor risk factor had a better chance of survival than
patients with three risk factors. These deviations from the weights
used by the IGCC classification did, however, not lead to
improvements in discriminative ability, in contrast with what we
expected. The use of Cox regression and recursive partitioning did
allow for more flexible classifications with more subgroups,
leading to a small improvement in discriminative ability and 5-
year survival of 34% for the poorest risk patients.
It appears that the maximum discriminative ability might have
been reached with the current IGCC risk factors and coding,
making further improvement in discriminative ability difficult.
The risk factors selected for the IGCC classification are in
agreement with risk factors used in other studies on identifying
good and poor prognosis patients with NSGCT (Bajorin et al, 1991;
Table 4 Survival of the IGCC classification, the regression-based classifications 5R and 5Ri and classification 5T based on recursive partitioning
IGCC 5R 5Ri 5T
Group Surv (%) N Surv (%) N Surv (%) N Surv (%) N
Good 92 1691 92 1691 92 1691 91 1865
Intermediate 81 862 80 872 80 915 78 761
Poor 50 495 50 485 47 442 49 422
Surv¼5-year survival.
Table 5 Survival of subgroups within the IGCC classification, the regression-based classifications 5R and 5Ri and classification 5T based on recursive
partitioning
IGCC 5R 5Ri 5T
Group (Surv) Surv (%) N Surv (%) N Surv (%) N Surv (%) N
Good (X90%) 92 1691 92 1691 92 1691 91 1865
Intermediate (75–89%) 82 684 81 824 82 818 80 619
Good–poor (60–74%) 72 251 65 225 63 194 70 142
Intermediate–poor (40–59%) 51 321 48 169 51 188 51 376
Poor–poor (p40%) 37 101 34 139 36 157 35 46
Surv¼5-year survival. Cutoff points on sum score classification 5R: Good 0, Intermediate 2–9, Good–poor 10–16, Intermediate–poor 17–22, Poor–poor 422.
Figure 2 Survival curves for the five groups of the IGCC classification (A) and classifications 5R (B), 5Ri, (C) and 5T (D).
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lMead et al, 1992). Some other potentially useful risk factors
include age, lung metastases and abdominal mass size. However,
adding these three risk factors to the Cox model had no substantial
effect on discriminative ability (c increased from 0.73 to 0.74). One
could also consider using continuous codings of tumour markers,
but this would lead to an undesirable increase in complexity and
decrease in applicability.
The division into more prognostic groups is similar to another
division by recursive partitioning of poor prognosis patients
(Kollmannsberger et al, 2000). Kollmannsberger et al identified
three prognosis groups: a good-poor, intermediate-poor and poor-
poor risk group with 2-year survival rates of 84, 64 and 49%,
respectively. These survival rates are higher than the survival rates
of the good-poor, intermediate-poor and poor-poor risk groups
identified in the IGCC dataset. This may be due to the difference in
survival for the poor prognosis patients (72 vs 50%), and remains
when the difference in follow-up time is taken into account (2 vs 5
years). The data in Kollmannsberger et al (2000) are more recent
and improvements in treatment may have led to the difference in
survival.
The lack of improvement in discriminative ability in both the
classifications with three and five groups might also be explained
by the dominance of the good prognosis group, which has a similar
survival for all classifications and contains more than half of all
patients. We therefore examined whether discriminative ability
increased within the poor prognosis group of each classification.
Discriminative ability increased from 0.50 to 0.60, 0.63, 0.64 and
0.65 for the three poor prognosis groups of classifications 5T,
IGCC, 5R and 5Ri, respectively. Hence, some improvement was
noted within the IGCC poor prognosis group. Furthermore, even
though the c-statistic is often used and easy to interpret, it is not
suitable for detecting small differences in discriminative ability
(Harrell et al, 1996; Steyerberg et al, 2000).
Although the use of Cox regression and recursive partitioning
did not have a major effect on discriminative ability, they can still
be useful tools in the construction of future prognostic classifica-
tions when other criteria are taken into account. One of the
advantages of classifications such as the IGCC classification is its
simplicity. Classification 5T is reasonably simple with only a few
subgroups and the survival probability readily available. Classifi-
cation 5R is slightly more complicated because of the sum score
that has to be calculated. Finally, classification 5Ri is not so much
complicated as visually unattractive. Furthermore, survival esti-
mates for infrequent combinations of risk factors are not reliable
and therefore provide little information on the prognosis of
patients with these risk factors.
A disadvantage of the IGCC classification is its inflexibility.
More groups could be defined, but not in a straightforward
manner. Classification 5R and classification 5Ri are very
flexible with many possible cutoff points. Classification 5T is
less flexible due to the limited number of subgroups, but
flexibility could be increased by putting fewer restrictions on the
recursive partitioning allowing for more subgroups to be
identified.
The IGCC classification considered not just discrimination but
also simplicity and the size of the resulting prognostic groups and
was chosen by consensus from a shortlist of possible models,
which balanced these considerations. Consequently, in the IGCC
classification there is a lack of transparency; it is unclear how the
classification was constructed statistically because statistical
considerations were not the only criteria used to derive the
classification. Classification 5T shows very clearly how the
subgroups were derived from the successive splits in the risk
factors. Classification 5R shows the difference in importance
between the risk factors and how the risk factors are combined in a
sum score. Classification 5Ri could be presented in a similar way as
classification 5R, but interpretation of the main and interaction
effects is difficult.
The IGCC dataset suffers from a number of limitations. First,
not all data were used for the multivariable regression
models because of missing data. When patients with missing
data differ from the other patients on prognosis, this causes a bias
in the regression coefficients and the estimated 5-year survival
rates (Little, 1992; van Buuren et al, 1999; Clark and Altman,
2003). Secondly, we could not internally validate the IGCC
classification, because the exact steps taken in the modelling
process (selection and categorisation of risk factors) were not
defined. The IGCC classification was applied to a 30% validation
set (IGCCCG, 1997), and although the proportion of patients in
each prognostic group was similar, the 5-year survival for
poor prognosis patients was higher (57%). We did internally
validate the modelling steps of the Cox regression models and
found minor optimism in discriminative ability. Classification 5T,
based on recursive partitioning, however, showed optimism in
discriminative ability, as might be expected from a more data-
driven method. This, in combination with the poorer performance,
suggests that recursive partitioning is less suitable for the
construction of prognostic classifications. It can be useful,
however, for exploratory analyses in finding interactions between
risk factors.
The survival estimates of the IGCC classification were also
externally validated with more recent data from an MRC/EORTC
trial (N¼300). The 2-year PFS outcome largely corresponded with
the IGCC estimates (IGCCCG, 1997). To gain further insight in the
generalisability of the Cox regression models as well as the IGCC
classification, further external validation is necessary, in larger
recent datasets with longer follow-up.
In conclusion, the IGCC classification appears to be a valid way
to classify patients with NSGCT in three prognostic groups.
Recursive partitioning is less suitable for the construction of
prognostic classifications, because of its poorer performance.
Although Cox regression did not lead to a clear improvement in
performance, it gave a more flexible and transparent scoring
system without much loss in simplicity. We therefore recommend
the use of regression-based weights in the development of future
prognostic classifications.
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Table 6 5-year survival estimates and number of patients are given for all 108 combinations of the IGCC risk factors based on a Cox regression model of
the IGCC risk factors and interactions AFP and primary site, AFP and NPVM, HCG and NPVM, and HCG and LDH
Primary site Primary site
Testis Mediastinum
NPVM NPVM NPVM NPVM
No Yes No Yes
AFP HCG LDH Surv (%) N Surv (%) N Surv (%) N Surv (%) N
Good 92 1691 79 27 53 14 18 1
Good Intermediate 83 459 60 31 25 12 2 10
Poor 73 11 43 3 10 0 0 1
Good 77 81 54 9 15 3 1 0
Good Intermediate Intermediate 66 62 38 16 5 1 0 1
Poor 60 2 30 0 2 0 0 0
Good 64 16 39 8 4 0 0 0
Poor Intermediate 59 56 32 38 2 1 0 2
Poor 61 0 35 3 3 0 0 0
Good 88 121 79 5 65 8 44 1
Good Intermediate 76 104 60 18 39 14 17 6
Poor 64 0 43 1 21 0 5 0
Good 69 16 54 1 28 0 12 0
Intermediate Intermediate Intermediate 55 19 37 9 13 0 3 0
Poor 48 1 30 3 8 0 2 0
Good 52 2 38 1 11 0 4 0
Poor Intermediate 46 13 32 3 7 0 2 0
Poor 49 3 35 0 9 0 3 0
Good 81 16 76 5 71 4 64 1
Good Intermediate 63 43 55 24 48 17 38 3
Poor 47 2 37 3 30 0 20 0
Good 54 4 49 0 37 0 32 0
Poor Intermediate Intermediate 37 10 31 0 20 0 16 0
Poor 29 0 21 0 14 0 10 0
Good 33 0 33 1 17 0 17 0
Poor Intermediate 27 1 26 3 12 1 12 0
Poor 30 0 29 2 15 0 14 0
Surv¼5-year survival; N¼number of patients. Classification into three groups; good prognosis 5-year survival 490%, intermediate prognosis 5-year survival 65–89%, poor
prognosis 5-year survival o65%. Classification into five groups; good prognosis 5-year survival 490%, intermediate prognosis 5-year survival 75–89%, good-poor prognosis 5-
year survival 60–74%, intermediate-poor prognosis 5-year survival 40–59%, Poor-poor prognosis 5-year survival o40%.
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